(Press-News.org) (WASHINGTON, June 4, 2012) – Results from a study published online today in Blood, the Journal of the American Society of Hematology (ASH), demonstrate that inclusion of carfilzomib, a novel targeted therapy for multiple myeloma, in combination with lenalidomide and low-dose dexamethasone, resulted in complete or near complete remission in a majority of patients with newly diagnosed multiple myeloma.
Multiple myeloma is cancer of the plasma cells, the white blood cells in the bone marrow that normally produce infection-fighting antibodies. Myeloma tumor cells overproduce certain antibodies, which may damage the kidneys and other organs, weaken the normal immune system, and also commonly cause bone destruction, leading to pain and fractures.
Until recently, chemotherapy and steroids were used as standard treatments for multiple myeloma. However, these traditional therapies are not very effective at eradicating tumor cells and generally cause high toxicities, as they destroy normal bone marrow cells along with tumor cells. In recent years, the introduction of new drugs, such as bortezomib, lenalidomide, and thalidomide, specifically toxic to tumor cells as compared to normal cells, has revolutionized the treatment of multiple myeloma, increasing the depth and duration of remissions and extending the life of myeloma patients, with limited toxicity as compared to standard chemotherapy. An emerging agent for the treatment of multiple myeloma is carfilzomib, a second-generation proteasome inhibitor, that has shown promising results in clinical trials involving patients with relapsed (disease that returns after a successful course of treatment) and/or refractory (disease that does not respond to treatment) multiple myeloma.
"In addition to demonstrating promising single-agent activity, a prior study investigating carfilzomib when combined with lenalidomide and low-dose dexamethasone in relapsed multiple myeloma has shown that the combination provides very encouraging responses with lower toxicity, as compared with standard treatment approaches," said Andrzej Jakubowiak, MD, PhD, the study's first author and Professor of Medicine at The University of Chicago School of Medicine. "Our study aimed at investigating the agent's efficacy and safety in newly diagnosed multiple myeloma with this fairly novel treatment regimen."
Led by Dr. Jakubowiak, investigators performed a multicenter phase I/II trial involving 53 patients with newly diagnosed multiple myeloma who received a carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) regimen in 28-day cycles for up to 24 treatment cycles (initial cycles followed by CRd maintenance) or until disease progression or intolerable toxicity.
Study results indicate that patients experienced a rapid and good initial response to CRd, and their responses improved as the trial continued. Of the 49 patients who completed four treatment cycles, 67 percent achieved at least near complete response (nCR), with 45 percent in stringent complete response (sCR), defined as no detectable tumor cells or myeloma protein in the blood or bone marrow. Of the 36 patients who completed eight or more treatment cycles, 78 percent achieved nCR with 61 percent in sCR. Overall, 62 percent of trial participants had achieved at least nCR,with 42 percent achieving sCR. The investigators also found progression-free survival (PFS) rates were 97 percent at 12 months and 92 percent at 24 months, with all patients who achieved sCR maintaining response for a median of nine months, demonstrating the durability of responses to this regimen. Importantly, these periods of extended treatment were well tolerated, including low rates of peripheral neuropathy, a treatment-limiting side effect of bortezomib, the first-generation proteasome inhibitor.
"Our final results continue to demonstrate the efficacy and safety of carfilzomib when combined with lenalidomide and dexamethasone," said Dr. Jakubowiak. "Our data support the potential for CRd as a new frontline treatment option for patients with multiple myeloma with results that are comparable to or better than those achieved with other established frontline regimens followed by high-dose chemotherapy and stem cell transplant."
Dr. Jakubowiak and other investigators are continuing to study this novel drug regimen in the ongoing phase III ASPIRE trial to evaluate lenalidomide and dexamethasone with or without carfilzomib in relapsed myeloma. The U.S. Food and Drug Administration is currently reviewing carfilzomib for the treatment of relapsed and refractory myeloma.
"Our hope is that our results will provide an effective treatment option for patients with multiple myeloma to help bring us one day closer to curing this deadly disease," added Dr. Jakubowiak.
###This manuscript was presented as an abstract at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2012.
The American Society of Hematology is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology. The official journal of ASH is Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online.
About 75 percent of children with leukemia who take chemotherapy face life-threatening heart problems as they age, but an international study led by a University of Rochester Medical Center investigator shows that giving a cardio-protective drug during cancer treatment may prevent the damage.
Researchers and physicians will debate how to make young cancer patients and their families aware of the risks of heart damage, and the best ways to manage the risks, in a special session today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
Led by Barbara ...
CallPro CRM announces its ability to integrate with QuickBooks, both the enterprise and cloud-based versions. QuickBooks is the most popular accounting software used by the U.S. SMB market. By enabling customers to integrate their CallPro CRM system with QuickBooks, CallPro CRM provides significantly added value.
Peter Connell, CEO of CallPro CRM says, "Many of our current clients are small to medium businesses. Since QuickBooks is so popular with these businesses we wanted to make sure we provided this functionality with CallPro CRM. Also, we hope to attract Intuit ...
Jointly released by ESRF - TU München and Synchrotron SOLEIL
Scientists have developed an X-ray imaging method that could drastically improve the contrast of computed tomography (CT) scans whilst reducing the radiation dose deposited during the scan. The new method is based on the combination of the high contrast obtained by an X-ray technique known as grating interferometry with the three-dimensional capabilities of CT. It is also compatible with clinical CT apparatus, where an X-ray source and detector rotate continuously around the patient during the scan. The results ...
Dr. Marina Kostina and Dr. William LaGanza, online education experts, have released their first book together, The Golden Climate in Distance Learning, which promises to be unlike any previous books on distance learning. Early reviews have been positive, noting that the book is well researched, engaging, and ideal for serious online instructors and trainers.
The Golden Climate in Distance Learning addresses an essential dimension for distance learning teachers and trainers: How to BE with your students and trainees so as to increase their connectivity, engagement, enjoyment, ...
Cambridge, Mass. - June 4, 2012 - A pair of new studies by computer scientists, biologists, and cognitive psychologists at Harvard, Northwestern, Wellesley, and Tufts suggest that collaborative touch-screen games have value beyond just play.
Two games, developed with the goal of teaching important evolutionary concepts, were tested on families in a busy museum environment and on pairs of college students. In both cases, the educational games succeeded at making the process of learning difficult material engaging and collaborative.
The findings were presented at the ...
It's well known that a relatively small percentage of chronically ill patients accounts for a disproportionate amount of health care dollars. Now, a multicenter study led by Johns Hopkins researcher Bruce Leff, M.D., might provide insights into how to cut Medicare costs while improving health care for older adults suffering from chronic health conditions.
Results of the study, published in the June issue of the journal Health Affairs, highlight the early efforts of the Medicare Innovations Collaborative, a joint program involving six health care-related organizations ...
Since the first casinos emerged online, video slot machines have been a driving force in the industry. Slots are charming, thrilling and fun to play. Slots have worldwide allure. Slots are also inviting and easy to learn, which makes them a great tool for attracting new players who might not otherwise take the plunge.
Online Slots and the Paradigm Shift
Recently, the industry experienced a paradigm shift: The slot machine was no longer solely the domain of the gambler. Gamers began flocking to video slots with arcade modes. Smartphone and tablet users are downloading ...
Picture a stereotypical tough guy and you might imagine a man with a broad face, a square jaw, and a stoical demeanor. Existing research even supports this association, linking wider, more masculine faces with several less-than-cuddly characteristics, including perceived lack of warmth, dishonesty, and lack of cooperation. But a new study suggests that men with these wide, masculine faces aren't always the aggressive tough guys they appear to be.
"Men with wider faces have typically been portrayed as 'bad to the bone,'" says psychologist Michael Stirrat. But he and David ...
Using a Johns Hopkins-developed program that allows medical professionals to provide acute hospital-level care within a patient's home, a New Mexico health system was able to reduce costs by roughly 20 percent and provide equal or better outcomes than hospital inpatients, according to new research.
"Hospital at Home is an excellent model of care that can be implemented in a practical way by health delivery systems across the country and can have dramatic positive clinical and economic outcomes for patients and systems," says Bruce Leff, M.D., the Johns Hopkins professor ...
The Rottenstein Law Group, which represents clients with claims stemming from injuries and birth defects caused by Selective Serotonin Reuptake Inhibitors (SSRIs) Zoloft and Paxil, has learned of research suggesting that pregnant women who take SSRIs to treat depression might be putting themselves at risk of going into earlier labor, or the rare occurrence of their newborn infants experiencing seizures.
According to a May 30 Reuters article, new findings published in the May 2, 2012 online edition of the American Journal of Obstetrics and Gynecology taken from a study ...
